Adverse Drug Reaction Classification System

ADR Ontology
ADR Term Neuroendocrine tumour
ADR ID BADD_A08102
ADR Hierarchy
05      Endocrine disorders
05.08      Neoplastic and ectopic endocrinopathies
05.08.01      Endocrine neoplasms NEC
05.08.01.013      Neuroendocrine tumour
16      Neoplasms benign, malignant and unspecified (incl cysts and polyps)
16.24      Endocrine neoplasms malignant and unspecified
16.24.01      Endocrine neoplasms malignant and unspecified NEC
16.24.01.009      Neuroendocrine tumour
Description Tumors whose cells possess secretory granules and originate from the neuroectoderm, i.e., the cells of the ectoblast or epiblast that program the neuroendocrine system. Common properties across most neuroendocrine tumors include ectopic hormone production (often via APUD CELLS), the presence of tumor-associated antigens, and isozyme composition. [MeSH]
MedDRA Code 10052399
MeSH ID D018358
ADR Severity Grade (FAERS)
ADR Severity Grade (CTCAE) Not Available
Synonym
Neuroendocrine tumour | Neuroendocrine tumor | Neuroendocrine Tumors | Neuroendocrine Tumor | Tumor, Neuroendocrine | Tumors, Neuroendocrine
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D00014Abiraterone0.000901%
BADD_D00329Cabergoline0.004804%
BADD_D00680Dimethyl fumarate0.000800%
BADD_D00858Everolimus0.002905%
BADD_D01136Imatinib0.000112%
BADD_D01245Lansoprazole0.000298%
BADD_D01401Metformin0.000022%
BADD_D01637Oxcarbazepine0.000170%
BADD_D01909Ramipril0.000093%
BADD_D01913Ranitidine0.000055%
BADD_D02100Sunitinib0.000851%
BADD_D02412Octreotide0.001211%
BADD_D02464Fingolimod0.000362%
BADD_D02568Lutetium oxodotreotide lu-177-
The 1th Page    1    Total 1 Pages